GONAL- f behandling for hver af indikationerne fører sjældent til signifikant OHSS, medmindre medicinen man anvender for at inducere afsluttende follikelmodning (indeholdende humant chorionic gonadotropin - hCG) er indgivet.
GONAL-f treatment in either indication seldom gives rise to significant OHSS unless the medicine used to induce final follicular maturation (containing human chorionic gonadotrophin - hCG) is administered.